for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

BioVie Inc

BIVI.OQ

Latest Trade

7.52USD

Change

-0.22(-2.84%)

Volume

51,925

Today's Range

7.51

 - 

7.84

52 Week Range

7.15

 - 

46.00

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
7.74
Open
7.66
Volume
51,925
3M AVG Volume
1.29
Today's High
7.84
Today's Low
7.51
52 Week High
46.00
52 Week Low
7.15
Shares Out (MIL)
24.83
Market Cap (MIL)
186.75
Forward P/E
-1.46
Dividend (Yield %)
--

Next Event

BioVie Inc at Oppenheimer Fall Healthcare Life Sciences & MedTech Summit (Virtual)

Latest Developments

More

Biovie Inc. Announces Pricing Of Public Offering Of Common Stock

BioVie Announces Proposed Public Offering Of Common Stock

BioVie Gets FDA Guidance For Phase 3 Clinical Trial Of BIV201 In HRS-AKI

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About BioVie Inc

BioVie Inc. clinical-stage company pursuing the discovery, development, and commercialization of drug therapies for liver disease. The Company is focused on developing and commercializing BIV201 (continuous infusion terlipressin) an approach to the treatment of ascites due to chronic liver cirrhosis. BIV201 also has an Orphan Drug designation for the treatment of hepatorenal syndrome (HRS). The Company is developing BIV201, a treatment option for patients suffering from ascites and other life-threatening complications of advanced liver cirrhosis caused by hepatitis, nonalcoholic steatohepatitis (NASH) and alcoholism. The Company is also engaged in developing NE3107, an ERK inhibitor that selectively reduces neuroinflammation and insulin resistance.

Industry

Biotechnology & Drugs

Contact Info

2120 Colorado Ave Ste 230

SANTA MONICA, CA

90404-3559

United States

+1.310.4444300

http://www.biovieinc.com/

Executive Leadership

Terren S. Peizer

Chairman of the Board

Cuong Viet Do

President, Chief Executive Officer

J. Wendy Kim

Chief Financial Officer, Corporate Secretary

Jonathan M. Adams

Chief Operating Officer

Penelope Markham

Chief Scientific Officer

Key Stats

2.00 mean rating - 1 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2021

0.0K

2022(E)

0.0K
EPS (USD)

2021

-14.830

2022(E)

-5.150
Price To Earnings (TTM)
--
Price To Sales (TTM)
--
Price To Book (MRQ)
33.25
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
--
Return on Equity (TTM)
-3,203.92

Latest News

Latest News

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up